Healthtech HR platform Jobizo raises Rs 12 Cr in Pre-Series A Round

IMT News Desk
IMT News Desk
· 2 min read

The funds will be used to strengthen technology, expand marketing efforts, grow the team, and support working capital needs

Jobizo, a leading healthtech HR platform, has raised Rs 12 crores in its Pre-Series A round from Inflection Point Ventures (IPV) and Alkemi Ventures. The funds will be deployed to accelerate product innovation, scale marketing efforts, bolster team strength, and support working capital needs.

Jobizo was launched to address critical gaps in healthcare staffing from urgent short-term hiring and undertrained professionals to system-wide inefficiencies. The platform leverages smart technology to connect healthcare institutions with pre-verified professionals for both temporary and permanent roles.

Vinay Bansal, Founder, Inflection Point Ventures, says, “Currently, healthcare is facing a major manpower crunch. It is reflected in the shortage and mismatch of healthcare talent. Jobizo is bridging the gap between healthcare and qualified professionals by making hiring faster, more flexible and digital thus solving multiple pain points across the healthcare employment ecosystem.”

“This round gives us the fuel to deepen our technology stack and expand across both domestic and international markets,” says Avishek Agarwal, CEO and Co-Founder. “We are laser-focused on bridging the global healthcare skills gap while offering flexible, meaningful job opportunities. Strengthening our core team and launching in more cities will be a key part of our growth roadmap.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk